Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Plichta on Areas of Interest for Genetic Testing Research in Breast Cancer

March 14th 2024

Jennifer K. Plichta, MD, MS, discusses key areas of interest regarding the role and optimization of genetic testing in breast cancer.

Dr Hwang on the Potential Use of Multicancer Early Detection Tests in Breast Cancer Screening

March 14th 2024

Shelley Hwang, MD, MPH, discusses the potential use of multicancer early detection tests in breast cancer screening.

Japanese Approval Sought for Datopotamab Deruxtecan in Pretreated HR+/HER2– Advanced Breast Cancer

March 14th 2024

A new drug application seeking the approval of Dato-DXd for pretreated HR-positive, HER2-negative advanced breast cancer has been filed in Japan.

Clinical Scenario: A 65-Year-Old Post-Menopausal Woman With Metastatic Breast Cancer

March 14th 2024

Oncologists present the clinical scenario of a 65-year-old woman with recurrent HR-positive, HER2-low breast cancer, and discuss optimal sequencing of systemic therapies in this setting.

Sequencing Therapies in the Third-Line and Beyond for Patients With HER2+ Metastatic Breast Cancer

March 14th 2024

Doctors Laura Spring and Manali Bhave discuss summarize their recommended sequence of systemic therapy options for HER2-positive metastatic breast cancer, from first-line taxane and dual HER2 blockade through later lines with T-DM1, tucatinib, and other regimens.

State of the Science Summit - Breast Cancer: Chaired by Komal Jhaveri, MD, FACP

March 14th 2024

State of the Science Summit - Breast Cancer: Chaired by Komal Jhaveri, MD, FACP

Dr Jimenez on the Radiation Treatment Paradigm in Breast Cancer

March 13th 2024

Rachel Jimenez, MD, discusses unmet needs in radiation treatment for patients with breast cancer.

Evolving and Current Standards of Care for HER2+ Early Breast Cancer

March 12th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.

Dr McCann on Navigating Work-Life Balance As a Woman in Oncology

March 12th 2024

Kelly E. McCann, MD, PhD, discusses her experiences with mentorship and work-life balance as a woman in oncology.

Prognosis and Survival Outcomes for HER2+ Early Breast Cancer

March 12th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.

Dr Graff on the Trajectory of Her Career in Breast Cancer

March 11th 2024

Stephanie L. Graff, MD, discusses the trajectory of her career growth in breast oncology and explains how different factors can play a role in an oncologist’s career path.

Dr Rugo on Challenges Faced as a Woman in Oncology

March 11th 2024

Hope S. Rugo, MD, discusses challenges that women face in the workplace in oncology care.

MRD Testing Presents Challenges and Opportunities in Breast Cancer Care

March 10th 2024

Heather McArthur, MD, MPH, discusses the prognostic benefits of circulating tumor DNA and limitations that prevent these results from being predictive.

Dr Tripathy on the Management of Early-Stage HER2+ Breast Cancer

March 10th 2024

Debu Tripathy, MD, discusses current considerations for the management of early-stage HER2-positive breast cancer.

Dr Rugo on the Evolution of ADCs in HR+/HER2+ and HER2-Low Breast Cancer

March 9th 2024

Hope Rugo, MD, discusses the evolution of antibody-drug conjugates in hormone receptor–positive, HER2-positive, and HER2-low breast cancer.

Targeted Agents Expand the HR+/HER2– Metastatic Breast Cancer Treatment Arena

March 9th 2024

Erica Stringer-Reasor, MD, highlights the evolution of therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr Park on the FDA Vote Supporting Lumisight Use for Breast Cancer Detection During Surgery

March 9th 2024

Ko Un “Clara” Park, MD, discusses the FDA's vote in support of Lumisight for patients with breast cancer undergoing breast conserving surgery.

FDA's MIDAC Votes in Support of Benefit-Risk Profile of Lumisight Optical Imaging Agent for Breast Cancer Detection

March 9th 2024

The FDA's Medical Imaging Drugs Advisory Committee voted 16 to 2 in support of the benefit-risk profile of Lumisight.

Dr Huppert on Data Informing the Sequence of Systemic Therapy in Early-Stage TNBC

March 9th 2024

Laura A. Huppert, MD, discusses data informing the sequence of immunotherapy and chemotherapy regimens in early-stage triple-negative breast cancer.

Neoadjuvant Chemotherapy Has Led to De-Escalation of Breast Cancer Surgery and Radiation

March 8th 2024

Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.